think that studying macro-vascular events will make an important contribution in the area
of type 2 diabetes. So we are at this time focused on making certain studies properly
sized and designed to address that issue because that would make the most important
contribution to the field.
questions and one was just a follow on related to the event driven trial that you have
mentioned, and my question was are the events driving this, are they going to be macro-
vascular events; micro-vascular events or both? The reason I am asking is obviously we
are all interested in a CV outcomes trial. Glucose control hasn't been shown to decrease
macro-vascular events. It has been shown to decrease micro-vascular events and we are
assuming that that is the same for this class of agents, which have not yet been shown to
decrease micro-vascular events. So I am just curious what these events actually are going
Scribes, LLC Toll Free 1-800-675-8846 www.scribesllc.com
DR. WOLF: Again, the design of that study is still under discussion. We
understand a little bit better the cardiovascular risk level of these patients, and I just had a
couple of specific questions. When you reported the percent that had
hypercholesterolemia, was that based on their reported past medical history or their
baseline lipid profile at entry?
DR. WYNE: Yes. I had two questions related to Dr. Teerlink's
DR. WYNE: Thank you, and my other question is just trying as he was to
whether or not there was any specific Statin used at a high level in either of the specific
studies or the global population?
DR. WOLF: That was based upon the reported past medical history by the
DR. WYNE: Okay. Do you know what percent were on Statins and